20/20 Biolabs (NASDAQ:AIDX) Raised to Hold at Wall Street Zen

Posted by on Mar 16th, 2026

20/20 Biolabs (NASDAQ:AIDX – Get Free Report) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

20/20 Biolabs Price Performance

Shares of NASDAQ:AIDX opened at $2.53 on Friday. 20/20 Biolabs has a one year low of $2.36 and a one year high of $50.00.

20/20 Biolabs Company Profile

(Get Free Report)

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.

Read More

Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.